Borr Drilling BORR
Three insiders bought $49.7M over 30 days, within the 30-day window
Last open-market buy
- Tor Olav Troim $48M
- Harvey Edward Snowling $1.5M
- De Oliveira Bruno Morand $200K
Form 4
Insider buys and sales
Source: Form 4 filings on SEC EDGAR
Type a ticker for one company's Form 4s, or read today's open-market trades at companies with a public float under $300M (All companies is one tap away): buys first, then sales, cluster buys and each insider's record across companies.
Open-market buys, last day2
Cluster buys, last 30 days, all companies14
Open-market sales, last day9
Planned sales (10b5-1), last day20
Insiders you follow
Cluster buys, last 30 days, all companies
6 of 14 companies whose last cluster buy was in the last 30 days, those with a public float under $2B first.
Pampa Energy PAM
Three insiders bought $42.7M over 21 days, within the 30-day window
Last open-market buy
- Marcos Marcelo Mindlin $35.1M
- Damian Miguel Mindlin $5.6M
- Gustavo Mariani $2M
Northpointe Bancshares NPB
Four insiders bought $1.8M over 6 days, within the 30-day window
Last open-market buy
- Charles Alan Williams $1.5M
- Carrie L Boer $185K
- Joseph B Long $50K
- Rajeev Kumar Chaudhary $47K
Rapport Therapeutics RAPP
Six insiders bought $1.7M over 3 days, within the 30-day window
Last open-market buy
- Steven M Paul $974K
- John Maraganore $249K
- Troy A. Ignelzi $144K
- Wendy B. Young $100K
- Paul M Silva $100K
- Ramiro Sanchez $98K
Stewart Information Services STC
Five insiders bought $461K over 4 days, within the 30-day window
Last open-market buy
- Frederick H Eppinger $133K
- Thomas G Apel $95K
- C Allen Bradley Jr $95K
- William S. Corey Jr. $94K
- Deborah Jane Matz $44K
Dynex Capital DX
Four insiders bought $295K over 26 days, within the 30-day window
Last open-market buy
- Smriti Laxman Popenoe $157K
- Byron L Boston $100K
- Terrence John Connelly JR $28K
- Michael Andrew Sartori $11K
Trades filed since Nov 3
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.
| Traded | Company | Insider | Trade | Value | Stake | Notes |
|---|---|---|---|---|---|---|
| Nov 2, 2026 Filed Nov 3, 2026 | ProMIS Neurosciences PMN | Neil Cashman Chief Scientific Officer | Open-market buy 10,000 shares | $39K at $3.86 | +221% | First open-market buy here in 1 year. 80 days after the company's SCHEDULE 13G/A filed Aug 14, 2026. |
| Oct 30, 2026 Filed Nov 3, 2026 | ProMIS Neurosciences PMN | Eugene Williams Director | Open-market buy 1,316 shares | $5K at $3.99 | +11% | Their first open-market buy here in SEC Tracker's records. 77 days after the company's SCHEDULE 13G/A filed Aug 14, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Replimune Group REPL | Kapil Dhingra Director | Open-market sale 21,500 shares | $409K at $19.00 | −50% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Icon ICLR | Barry Edward Balfe CEO | Open-market sale 1,509 shares | $311K at $206.15 | −11% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Icon ICLR | Barry Edward Balfe CEO | Open-market sale 1,314 shares | $273K at $208.00 | −12% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Artiva Biotherapeutics ARTV | Fred Aslan CEO | Open-market sale 62,178 shares | $260K at $4.18 | −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. 6 days after the company's 8-K filed Oct 27, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Icon ICLR | Barry Edward Balfe CEO | Open-market sale 1,224 shares | $254K at $207.16 | −10% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Icon ICLR | Barry Edward Balfe CEO | Open-market sale 1,053 shares | $216K at $204.91 | −7% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Intellia Therapeutics NTLA | John M Leonard CEO | Planned sale (10b5-1) 9,000 shares | $108K at $11.99 | −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Oct 30, 2026 Filed Nov 2, 2026 | Nurix Therapeutics NRIX | Christine Ring CLO | Open-market sale 3,957 shares | $104K at $26.28 | −21% | The filing does not mark this sale as under a Rule 10b5-1 plan. 16 days after a Form 144 notice of a planned insider sale filed Oct 14, 2026. |
| Oct 30, 2026 Filed Nov 2, 2026 | Nurix Therapeutics NRIX | Gwenn Hansen Chief Scientific Officer | Planned sale (10b5-1) 3,957 shares | $104K at $26.28 | −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 16 days after a Form 144 notice of a planned insider sale filed Oct 14, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Icon ICLR | Nigel Bernard John Clerkin CFO | Open-market sale 434 shares | $89K at $206.15 | −5% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Icon ICLR | Nigel Bernard John Clerkin CFO | Open-market sale 377 shares | $78K at $208.00 | −5% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
18 open-market sales at companies with a public float of $2B or more are under Everything.
Insider records
The 9 insiders in these trades with the most bought and sold on the open market across every company, in SEC Tracker's records.
| Insider | Buys | Sales | Bought | Sold | Companies |
|---|---|---|---|---|---|
| Kapil Dhingra | 0 | 5 | $2.3M | 1 | |
| Barry Edward Balfe | 0 | 7 | $1.1M | 1 | |
| Fred Aslan | 0 | 2 | $413K | 1 | |
| Nigel Bernard John Clerkin | 0 | 5 | $308K | 1 | |
| Gwenn Hansen | 0 | 3 | $195K | 1 | |
| Christine Ring | 0 | 2 | $151K | 1 | |
| John M Leonard | 0 | 1 | $108K | 1 | |
| Neil Cashman | 2 | 0 | $53K | 1 | |
| Eugene Williams | 1 | 0 | $5K | 1 |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.